Synthetic Lethality and Cancer - Penetrance as the Major Barrier

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Synthetic lethality is a promising strategy for targeting genetic defects in tumors.
• Despite extensive screening, few robust synthetic lethal targets have been identified.
• Recent advances in genetic perturbation technologies like CRISPR/Cas9 have renewed interest in cancer research.

Purpose of the Study:

• To address the challenge of identifying robust synthetic lethal interactions (SLIs) for cancer therapy.
• To investigate the limitations of current approaches in discovering clinically relevant SLIs.
• To propose strategies for identifying highly penetrant SLIs that are effective against tumor molecular heterogeneity.

Main Methods:

• Review of existing screening efforts and genetic perturbation technologies.
• Analysis of the impact of molecular heterogeneity on the penetrance of SLIs.
• Development of a framework for prioritizing SLIs based on their robustness.

Main Results:

• The primary limitation in identifying synthetic lethal targets is not technology but the low penetrance of most SLIs.
• Most SLIs are not robust to the extensive molecular heterogeneity found in tumors.
• Strategies are needed to identify and prioritize SLIs that exhibit high penetrance.

Conclusions:

• The lack of robust synthetic lethal targets is primarily due to low penetrance, not technological limitations.
• Future research should focus on identifying synthetic lethal interactions that are highly penetrant and overcome tumor heterogeneity.
• Developing methods to prioritize robust SLIs is crucial for advancing synthetic lethality as a cancer treatment strategy.